Literature DB >> 24043463

Lessons learned from radiation oncology clinical trials.

Fei-Fei Liu1, Paul Okunieff, Eric J Bernhard, Helen B Stone, Stephen Yoo, C Norman Coleman, Bhadrasain Vikram, Martin Brown, John Buatti, Chandan Guha.   

Abstract

A workshop entitled "Lessons Learned from Radiation Oncology Trials" was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality and limitations of the preclinical data that supported the hypotheses underlying these trials, and to consider possible solutions to these challenges for the design of future clinical trials. Several themes emerged from the discussions: (i) opportunities to learn from null-hypothesis trials through tissue and imaging studies; (ii) value of preclinical data supporting the design of combinatorial therapies; (iii) significance of validated biomarkers; (iv) necessity of quality assurance in radiotherapy delivery; (v) conduct of sufficiently powered studies to address the central hypotheses; and (vi) importance of publishing results of the trials regardless of the outcome. The fact that well-designed hypothesis-driven clinical trials produce null or negative results is expected given the limitations of trial design and complexities of cancer biology. It is important to understand the reasons underlying such null results, however, to effectively merge the technologic innovations with the rapidly evolving biology for maximal patient benefit through the design of future clinical trials. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24043463      PMCID: PMC3965328          DOI: 10.1158/1078-0432.CCR-13-1116

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  67 in total

1.  Improving validation practices in "omics" research.

Authors:  John P A Ioannidis; Muin J Khoury
Journal:  Science       Date:  2011-12-02       Impact factor: 47.728

2.  Adaptive clinical trial design: has its time come?

Authors:  Nancy J Nelson
Journal:  J Natl Cancer Inst       Date:  2010-08-06       Impact factor: 13.506

3.  Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck.

Authors:  M T Sheridan; T O'Dwyer; C B Seymour; C E Mothersill
Journal:  Radiat Oncol Investig       Date:  1997

4.  A spatially and temporally restricted mouse model of soft tissue sarcoma.

Authors:  David G Kirsch; Daniela M Dinulescu; John B Miller; Jan Grimm; Philip M Santiago; Nathan P Young; G Petur Nielsen; Bradley J Quade; Christopher J Chaber; Christian P Schultz; Osamu Takeuchi; Roderick T Bronson; Denise Crowley; Stanley J Korsmeyer; Sam S Yoon; Francis J Hornicek; Ralph Weissleder; Tyler Jacks
Journal:  Nat Med       Date:  2007-08-05       Impact factor: 53.440

5.  Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer.

Authors:  C H Clark; E A Miles; M T Guerrero Urbano; S A Bhide; A M Bidmead; K J Harrington; C M Nutting
Journal:  Br J Radiol       Date:  2009-03-30       Impact factor: 3.039

6.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.

Authors:  R K Schmidt-Ullrich; R B Mikkelsen; P Dent; D G Todd; K Valerie; B D Kavanagh; J N Contessa; W K Rorrer; P B Chen
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

7.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Authors:  S M Huang; J M Bock; P M Harari
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

8.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

9.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

View more
  16 in total

Review 1.  Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.

Authors:  Anish Prasanna; Mansoor M Ahmed; Mohammed Mohiuddin; C Norman Coleman
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

Review 2.  Small animal image-guided radiotherapy: status, considerations and potential for translational impact.

Authors:  K T Butterworth; K M Prise; F Verhaegen
Journal:  Br J Radiol       Date:  2015-01       Impact factor: 3.039

3.  A novel data management platform to improve image-guided precision preclinical biological research.

Authors:  Lucas Persoon; Stefan van Hoof; Frank van der Kruijssen; Patrick Granton; Andrea Sanchez Rivero; Harold Beunk; Ludwig Dubois; Jan-Willem Doosje; Frank Verhaegen
Journal:  Br J Radiol       Date:  2018-10-11       Impact factor: 3.039

4.  Enhancing the efficacy of radiation therapy: premises, promises, and practicality.

Authors:  C Norman Coleman; Theodore S Lawrence; David G Kirsch
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 5.  Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.

Authors:  C Norman Coleman; Geoff S Higgins; J Martin Brown; Michael Baumann; David G Kirsch; Henning Willers; Pataje G S Prasanna; Mark W Dewhirst; Eric J Bernhard; Mansoor M Ahmed
Journal:  Clin Cancer Res       Date:  2016-05-06       Impact factor: 12.531

6.  Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.

Authors:  Dina V Hingorani; Matthew K Doan; Maria F Camargo; Joseph Aguilera; Seung M Song; Donald Pizzo; Daniel J Scanderbeg; Ezra E W Cohen; Andrew M Lowy; Stephen R Adams; Sunil J Advani
Journal:  Mol Cancer Ther       Date:  2019-10-09       Impact factor: 6.261

Review 7.  Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?

Authors:  Bridget F Koontz; Frank Verhaegen; Dirk De Ruysscher
Journal:  Br J Radiol       Date:  2016-09-26       Impact factor: 3.039

8.  A sparse orthogonal collimator for small animal intensity-modulated radiation therapy part I: Planning system development and commissioning.

Authors:  Kaley Woods; Dan Nguyen; Ryan Neph; Dan Ruan; Daniel O'Connor; Ke Sheng
Journal:  Med Phys       Date:  2019-11-04       Impact factor: 4.071

Review 9.  Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.

Authors:  Salma K Jabbour; Terence M Williams; Mutlay Sayan; Eric D Miller; Jaffer A Ajani; Andrew C Chang; Norman Coleman; Wael El-Rifai; Michael Haddock; David Ilson; Daniel Jamorabo; Charles Kunos; Steven Lin; Geoffrey Liu; Pataje G Prasanna; Anil K Rustgi; Rosemary Wong; Bhadrasain Vikram; Mansoor M Ahmed
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

10.  Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

Authors:  Lisa Buckel; Elamprakash N Savariar; Jessica L Crisp; Karra A Jones; Angel M Hicks; Daniel J Scanderbeg; Quyen T Nguyen; Jason K Sicklick; Andrew M Lowy; Roger Y Tsien; Sunil J Advani
Journal:  Cancer Res       Date:  2015-02-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.